B epitope multiplicity and B/T epitope orientation influence immunogenicity of foot-and-mouth disease peptide vaccines
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Blanco, Estherca
- dc.contributor.author Cubillos, Carolinaca
- dc.contributor.author Moreno, Noeliaca
- dc.contributor.author Bárcena, Juanca
- dc.contributor.author Torre, Beatriz G. de laca
- dc.contributor.author Andreu Martínez, Davidca
- dc.contributor.author Sobrino, Franciscoca
- dc.date.accessioned 2015-11-25T14:06:44Z
- dc.date.available 2015-11-25T14:06:44Z
- dc.date.issued 2013
- dc.description.abstract Synthetic peptides incorporating protective B- and T-cell epitopes are candidates for new safer foot-and-mouth disease (FMD) vaccines. We have reported that dendrimeric peptides including four copies of a B-cell epitope (VP1 136 to 154) linked to a T-cell epitope (3A 21 to 35) of FMD virus (FMDV) elicit potent B- and T-cell specific responses and confer protection to viral challenge, while juxtaposition of these epitopes in a linear peptide induces less efficient responses. To assess the relevance of B-cell epitope multivalency, dendrimers bearing two (B2T) or four (B4T) copies of the B-cell epitope from type O FMDV (a widespread circulating serotype) were tested in CD1 mice and showed that multivalency is advantageous over simple B-T-epitope juxtaposition, resulting in efficient induction of neutralizing antibodies and optimal release of IFN γ . Interestingly, the bivalent B2T construction elicited similar or even better B- and T-cell specific responses than tetravalent B4T. In addition, the presence of the T-cell epitope and its orientation were shown to be critical for the immunogenicity of the linear juxtaposed monovalent peptides analyzed in parallel. Taken together, our results provide useful insights for a more accurate design of FMD subunit vaccines.ca
- dc.description.sponsorship Research at CBMSO was funded by Spanish MINECO (BIO2011-24351), and by an institutional grant from Fundación Ramón Areces. Research at Universitat Pompeu Fabra was funded by the Spanish MINECO (SAF2011-24899) and by Generalitat de Catalunya (SGR2009-00492). Research at INIA was funded by the European Community’s Seventh Framework Programme (FP7, 2007-2013), Research Infrastructures action, under the grant agreement no. FP7-228394 (NADIR) and Spanish MINECO (AGL2010-22200-C02-02 and CC07-062). Noelia Moreno is a predoctoral (FPI) fellow from the Spanish MEC.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Blanco E, Cubillos C, Moreno N, Bárcena J, de la Torre BG, Andreu D et al. B epitope multiplicity and B/T epitope orientation influence immunogenicity of foot-and-mouth disease peptide vaccines. Clin Dev Immunol. 2013; 2013:475960. DOI: 10.1155/2013/475960ca
- dc.identifier.doi http://dx.doi.org/10.1155/2013/475960
- dc.identifier.issn 1740-2522
- dc.identifier.uri http://hdl.handle.net/10230/25214
- dc.language.iso engca
- dc.publisher Taylor & Francis Health (Routledge)ca
- dc.relation.ispartof Clinical & developmental immunology. 2013;2013:475960
- dc.rights © 2013 Esther Blanco et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.ca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.rights.uri http://creativecommons.org/licenses/by/3.0/
- dc.subject.other Immunoglobulines
- dc.subject.other Pèptids
- dc.subject.other Cèl·lules T
- dc.title B epitope multiplicity and B/T epitope orientation influence immunogenicity of foot-and-mouth disease peptide vaccinesca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/publishedVersionca